Actinium Pharmaceuticals
ATNM
41 hedge funds and large institutions have $23.1M invested in Actinium Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 29 closing their positions.
171% more call options, than puts
Call options by funds: $1.35M | Put options by funds: $498K
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
16.82% more ownership
Funds ownership: 0.73% → 17.56% (+17%)
24% less capital invested
Capital invested by funds: $30.5M → $23.1M (-$7.41M)
31% less funds holding
Funds holding: 59 → 41 (-18)
62% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$1.07M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$637K |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$634K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$525K |
| 5 |
Bank of New York Mellon
New York
|
+$469K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$4.85M |
| 2 |
Renaissance Technologies
New York
|
-$1.27M |
| 3 |
BlackRock
New York
|
-$1.13M |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1M |
| 5 |
SCM
Sio Capital Management
New York
|
-$910K |
ATNM Hedge Fund Activity: Q3 2020 in Review
41 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q3 2020, worth a combined $23.1M — down 24% from $30.5M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ATNM and 11 opened new positions — a net loss of 18 holders — while 10 trimmed existing stakes and 12 added.
The largest buyer was J. Goldman & Co, adding an estimated $1.07M. The largest seller was Consonance Capital Management, cutting an estimated $4.85M.
- 41 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q3 2020, down from 59 in Q2 2020.
- Funds reported $23.1M of Actinium Pharmaceuticals stock for Q3 2020, down 24% quarter-over-quarter.
- 11 funds opened new Actinium Pharmaceuticals positions in Q3 2020 and 29 closed out, a net change of -18 holders.
- The largest Actinium Pharmaceuticals buyer in Q3 2020 was J. Goldman & Co, an estimated $1.07M added.
- The largest Actinium Pharmaceuticals seller in Q3 2020 was Consonance Capital Management, an estimated $4.85M sold.
Based on aggregated 13F filings for Q3 2020.